General
Preferred name
AVANAFIL
Synonyms
TA1790 ()
4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-[(pyrimidin-2-yl)methyl]pyrimidine-5-carboxamide ()
TA-1790 ()
Stendra ()
Spedra ()
Avanafilo ()
AVANAFILO ()
SPEDRA ()
STENDRA ()
Avanafil-13C-d3 ()
P&D ID
PD000128
CAS
330784-47-9
2738376-89-9
Tags
available
drug
Approved by
FDA
EMA
First approval
2011
2012
Drug indication
Erectile dysfunction
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Avanafil is rapidly absorbed and does not accumulate following multiple doses. ; Tmax = 30 - 45 minutes;; Time to peak response = 10 minutes (20 minutes shorter than sildenafil)
DESCRIPTION Avanafil is a phosphodiesterase type 5 inhibitor. (GtoPdb)
DESCRIPTION Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis[1][2][3].
PRICE 29
DESCRIPTION Avanafil is a potent and highly selective phosphodiesterase-5 (PDE-5) inhibitor. It is used to treat erectile dysfunction (Enamine Bioactive Compounds)
DESCRIPTION Avanafil (TA1790) is a selective inhibitor of phosphodiesterase type 5 (PDE5) and is used as therapy of erectile dysfunction. (TargetMol Bioactive Compound Library)
Cell lines
3
Organisms
0
Compound Sets
22
AdooQ Bioactive Compound Library
A12619
Cayman Chemical Bioactives
23024
31687
ChEMBL Approved Drugs
CHEMBL1963681
ChEMBL Drugs
CHEMBL1963681
Drug Repurposing Hub
DrugBank
DB06237
DrugBank Approved Drugs
DB06237
DrugCentral
4305
DrugCentral Approved Drugs
4305
DrugMAP
DM75CXN
DrugMAP Approved Drugs
DM75CXN
Enamine Bioactive Compounds
EBC-03919
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101381
EUbOPEN Chemogenomics Library
EUB0002503
Guide to Pharmacology
7448
MedChem Express Bioactive Compound Library
HY-18252
NCATS Inxight Approved Drugs
DR5S136IVO
ReFrame library
Selleckchem Bioactive Compound Library
avanafil
TargetMol Bioactive Compound Library
T2334
The Spectrum Collection
External IDs
39
Properties
(calculated by RDKit )
Molecular Weight
483.18
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
3
cLogP
2.43
TPSA
125.39
Fraction CSP3
0.35
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PDE5
phosphodiesterase
PDE5A
Endogenous Metabolite
NO Synthase
Phosphodiesterase (PDE)
PDE
Indication
erectile dysfunction
MOA
phosphodiesterase inhibitor
Pathway
Metabolism
Immunology/Inflammation
Metabolic Enzyme/Protease
Recommended Cell Concentration
None
Source data